**Enrollment**

1. Assess eligibility
   - Include patients who do meet the Inclusion criteria
   - Exclude patients who meet the exclusion criteria
   - Obtain informed consent
   - Randomisation
   - N=492
     - n=246
       - Selenium
       - Concomitant anti-thyroid drug treatment
       - Follow up visit I: 18 months after randomisation
       - Concomitant anti-thyroid drug treatment
       - Placebo

**Intervention**

- Follow up visit II: 12 months after end of anti-thyroid drug treatment (approximately 24-30 months)
- Lost to follow-up (n=x, give reasons)
- Discontinued intervention (n=x, give reasons)

**Follow up**

- Final analysis (according to intention-to-treat)
  - Excluded from analysis (n=x, give reasons)